hpk1 inhibitors (Ryvu Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug Namehpk1 inhibitors (Ryvu Therapeutics)

Drug Alias NameMitogen-Activated Protein Kinase Kinase Kinase Kinase 1 (Ryvu Therapeutics)hematopoietic progenitor kinase 1 inhibitors (Ryvu Therapeutics)hpk1 inhibitors (Ryvu Therapeutics)RVU-895RVU-293 +[7]

ClassificationSmall molecules

Mechanisms of ActionImmunostimulantsMitogen-activated protein kinase kinase kinase kinase 1 inhibitorsAnticancer protein kinase inhibitors +[4]

TargetsMitogen-activated protein kinase kinase kinase kinase 1

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusN/A

Highest Status in ChinaN/A

Originator CompaniesRyvu Therapeutics Sa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRyvu Therapeutics Sa

Active IndicationsN/A

Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A